Abstract
Clinical evidence have shown SBRT to be a tolerable, efficacious, and promising non-invasive therapy. Randomized prospective studies comparing surgery vs. SBRT in early-stage lung cancer are proposed to further investigate the relative survival, quality of life, and cost characteristics of these treatment paradigms. Accreditation and dosimetry requirements were carefully vetted for RTOG SBRT trials. Advanced technologies introduced since have posed additional challenges. This study provides an overview of the quality requirements including those for the recently introduced technologies.
| Original language | English (US) |
|---|---|
| Title of host publication | World Congress on Medical Physics and Biomedical Engineering |
| Pages | 2284-2287 |
| Number of pages | 4 |
| Volume | 39 IFMBE |
| DOIs | |
| State | Published - Apr 16 2013 |
| Event | World Congress on Medical Physics and Biomedical Engineering - Beijing, China Duration: May 26 2012 → May 31 2012 |
Other
| Other | World Congress on Medical Physics and Biomedical Engineering |
|---|---|
| Country | China |
| City | Beijing |
| Period | 5/26/12 → 5/31/12 |
Fingerprint
Keywords
- clinical trials
- NSCLC
- quality
- SBRT
- Surgery
ASJC Scopus subject areas
- Bioengineering
- Biomedical Engineering
Cite this
Quality requirements for stereotactic body radiation therapy (SBRT) in multi-institutional clinical trials. / Xiao, Y.; Yin, F.; Kong, F. M.S.; Yue, J.; Galvin, J.
World Congress on Medical Physics and Biomedical Engineering. Vol. 39 IFMBE 2013. p. 2284-2287.Research output: Chapter in Book/Report/Conference proceeding › Conference contribution
}
TY - GEN
T1 - Quality requirements for stereotactic body radiation therapy (SBRT) in multi-institutional clinical trials
AU - Xiao, Y.
AU - Yin, F.
AU - Kong, F. M.S.
AU - Yue, J.
AU - Galvin, J.
PY - 2013/4/16
Y1 - 2013/4/16
N2 - Clinical evidence have shown SBRT to be a tolerable, efficacious, and promising non-invasive therapy. Randomized prospective studies comparing surgery vs. SBRT in early-stage lung cancer are proposed to further investigate the relative survival, quality of life, and cost characteristics of these treatment paradigms. Accreditation and dosimetry requirements were carefully vetted for RTOG SBRT trials. Advanced technologies introduced since have posed additional challenges. This study provides an overview of the quality requirements including those for the recently introduced technologies.
AB - Clinical evidence have shown SBRT to be a tolerable, efficacious, and promising non-invasive therapy. Randomized prospective studies comparing surgery vs. SBRT in early-stage lung cancer are proposed to further investigate the relative survival, quality of life, and cost characteristics of these treatment paradigms. Accreditation and dosimetry requirements were carefully vetted for RTOG SBRT trials. Advanced technologies introduced since have posed additional challenges. This study provides an overview of the quality requirements including those for the recently introduced technologies.
KW - clinical trials
KW - NSCLC
KW - quality
KW - SBRT
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=84876020076&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876020076&partnerID=8YFLogxK
U2 - 10.1007/978-3-642-29305-4_599
DO - 10.1007/978-3-642-29305-4_599
M3 - Conference contribution
SN - 9783642293047
VL - 39 IFMBE
SP - 2284
EP - 2287
BT - World Congress on Medical Physics and Biomedical Engineering
ER -